Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “GLUTAMIC ACID”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 325 records · Page 18Linked to original sources

Defining proximity relationships in the tertiary structure of the dopamine transporter. Identification of a conserved glutamic acid as a third coordinate in the endogenous Zn(2+)-binding site.

Recently, we have described a distance constraint in the unknown tertiary structure of the human dopamine transporter (hDAT) by identification of two histidines, His(193) in the second extracellular loop and His(375) at the top of transmembrane (TM) 7, that form two coordinates in an endogenous, high affinity Zn(2+)-binding site. To achieve further insight into the tertiary organization of hDAT, we set out to identify additional residues involved in Zn(2+) binding and subsequently to engineer artificial Zn(2+)-binding sites. Ten aspartic acids and glutamic acids, predicted to be on the extracellular side, were mutated to asparagine and glutamine, respectively. Mutation of Glu(396) (E396Q) at the top of TM 8 increased the IC(50) value for Zn(2+) inhibition of [(3)H]dopamine uptake from 1.1 to 530 microM and eliminated Zn(2+)-induced potentiation of [(3)H]WIN 35,428 binding. These data suggest that Glu(396) is involved in Zn(2+) binding to hDAT. Importantly, Zn(2+) sensitivity was preserved following substitution of Glu(396) with histidine, indicating that the effect of mutating Glu(396) is not an indirect effect because of the removal of a negatively charged residue. The common participation of Glu(396), His(193), and His(375) in binding the small Zn(2+) ion implies their proximity in the unknown tertiary structure of hDAT. The close association between TM 7 and 8 was further established by engineering of a Zn(2+)-binding site between His(375) and a cysteine inserted in position 400 in TM 8. Summarized, our data define an important set of proximity relationships in hDAT that should prove an important template for further exploring the molecular architecture of Na(+)/Cl(-)-dependent neurotransmitter transporters.

Amino Acid Sequence↗

[Clinical study of a phytosterol extract of Prunus arborea and 3 amino acids: glycine, alanine and glutamic acid].

We have carried out a therapeutic study on "Tebetane compuesto", by applying it to one hundred patients, whose pathologies, prostatic adenoma, prostatitis and postadenomectomy sequelas, come within the field of action of the product, as shown by other authors. The particular feature of "Tebetane compuesto" is that it is a non-hormonal product, which contributes to the fact that it may be used in high doses without producing harmful effects on the patient. We have found no cases of intolerance or side effects, which we feel makes it superior to other similar products. To be specific, in the case of prostatitis, "Tebetane compuesto" has proved to be effective in 94 per 100 of the patients treated, making it a highly reliable product for use by the specialist or general practitioner. We feel, on the other hand, that the inclusion in the formula of "Tebetane compuesto" of the three aminoacids has led to a considerable reduction in the duration of the treatments of these patients, with the resulting financial saving involved.

Aged↗

Characterization of specific, high-affinity binding sites for L-[3H]glutamic acid in rat brain membranes.

L-[3H]Glutamic acid binds reversibly to rat brain membranes with high affinity. Specific binding is linear with tissue concentration and has a pH optimum at neutrality. Saturation isotherms reveal anomolous kinetics of specific binding with an high affinity site with a KD of 11 nM and a lower affinity site with a KD of 80 nM; the Scatchard plots intercept at a common bound/free ratio. Hill plots of the complete saturation isotherms have a slope of 1.0. There are marked regional differences in the distribution of binding sites in rat brain: parietal cortex, frontal cortex, hippocampus greater than striatum greater than thalamus greater than cerebellum, pons-medulla and hypothalamus. Except for a small amount of specific binding in heart, other peripheral tissues do not exhibit specific binding of L-[3H]glutamic acid. Several amino acids with neuroexcitatory effects inhibit the specific binding: L-glutamic acid greater than L-aspartic acid and D,L-homocysteic acid greater than D-glutamic acid and L-cysteine sulfinic acid; related amino acids without neuroexcitatory effects do not inhibit specific binding. Reputed antagonists of glutamate-induced neuronal depolarization block specific binding: alpha-aminoadipic acid greater than 2-amino,4-phosphonobutyric acid greater than glutamate diethylester. Prior kainate lesion of the neurons intrinsic to the striatum results in a 45% decrement in specific binding of L-[3H]glutamic acid whereas cortical ablation, which causes degeneration of a cortical-striatal glutamatergic projection and reduces striatal glutamate synaptosomal uptake, does not affect specific binding. These results are compatible with the interpretation that the binding of [3H]glutamic acid occurs at excitatory receptors on neurons.

Animals↗

Synthesis and neuroprotective activity of analogues of glycyl-L-prolyl-L-glutamic acid (GPE) modified at the alpha-carboxylic acid.

The synthesis of nine GPE* analogues, wherein the alpha-carboxylic acid group of glutamic acid has been modified, is described by coupling readily accessible N-benzyloxycarbonyl-glycyl-L-proline 2 with various analogues of glutamic acid. Pharmacological evaluation of the novel compounds was undertaken to further understand the role of the glutamate residue on the observed neuroprotective properties of the endogenous tripeptide GPE.

Animals↗

Irreversible inhibition of glutamate decarboxylase by alpha-(fluoromethyl)glutamic acid.

alpha-(Fluoromethyl)glutamic acid (FMG) was synthesized and shown to be an active site directed irreversible inhibitor of glutamate decarboxylase (EC 4.1.1.15) from Escherichia coli. The KI for the active enantiomer is 1.4 microM, and the kinh = 5.9 X 10(-3) s-1. Substrates for the enzyme, such as L-glutamate, and competitive inhibitors, such as citrate, decrease the rates of FMG-mediated inactivation of the enzyme. A profound change in the ultraviolet spectrum of the enzyme accompanies the inactivation process. When [3H]-FMG is used, it can be shown that the enzyme incorporates radioactivity at the same rate as that of inactivation. There is a 1:1 stoichiometry of [3H]FMG incorporated to pyridoxal phosphate binding subunits of the enzyme. From these and other studies it is concluded that FMG is a substrate for the enzyme and alkylates it as a consequence of this turnover.

Binding, Competitive↗

[Prevention of dental fluorosis by glutamic acid].

The preventive effect of glutamic acid on the clinical manifestation of dental fluorosis was studied in rat experiments. Young rats receiving fluorinated (15 mg/liter) drinking water during 4-5 weeks developed depigmentation characteristic of dental fluorosis. No depigmentation was observed in rats receiving water with the same content of fluorine in parallel with glutamic acid (twice a week). The enamel in this latter group virtually did not differ from normal dental enamel in rats receiving standard vivarium rations. Hence, glutamic acid prevented dental fluorosis by neutralizing the toxic effect of high fluorine dose. Biochemical parameters of the blood (Ca, P, total protein, AlAT, AsAT) also indicated the corrective effect of this amino acid.

Animals↗

Function and metabolism of dog heart in ischemia and in subsequent reperfusion: effect of exogenous glutamic acid.

The effect of intravenous infusion of glutamic acid on cardiac contractile function during short-term ischemia and subsequent reperfusion was studied in anaesthetized dogs. Left ventricular ischemia was induced by underperfusion of the anterior descending and circumflex coronary arteries. Infusion of glutamic acid at 3 mg/kg/min resulted in less depression of cardiac function when given after a 2 min period of 60% coronary blood flow reduction: left ventricular systolic pressure decreased by 9% vs. 22%, dP/dt decreased by 16% vs. 29%, the double product (left ventricular systolic pressure by heart rate) was reduced by 16% vs. 31%. When reperfusion was carried out during glutamic acid infusion there was a significantly enhanced recovery in cardiac function. The augmentation of cardiac performance in ischemia and reperfusion caused by glutamic acid was not accompanied by changes in myocardial oxygen consumption. Glutamic acid uptake by the ischemic myocardium increased 2-fold during infusion. This led to cessation of ammonia release from the heart due to stimulation of glutamine synthesis, and an enhancement of alanine formation coupled with pyruvate uptake but it did not effect lactate production. However, glutamic acid infusion did not influence cardiac performance and metabolism under conditions of normal coronary flow. The results suggest that elevation of glutamate arterial concentration exerts a beneficial effect on ischemic heart. The mechanisms of the protective action are discussed.

Alanine↗

Chemical evolution of the citric acid cycle: sunlight photolysis of the amino acids glutamate and aspartate.

Sunlight photolysis of the amino acids glutamate and aspartate were carried out on 0.1 M aqueous solutions at pH = 7.0. The non-volatile products were identified by GC-MS analysis of derived methyl esters. The major product from glutamic acid was succinic acid, and, analogously, aspartic acid photolyzed to malonic acid. The photochemical oxidative decarboxylation of glutamate parallels its metabolism in modern cells and may provide an evolutionary link between simple amino acids and reactions of the citric acid cycle.

Aspartic Acid↗

Binding order of substrates to the sodium and potassium ion coupled L-glutamic acid transporter from rat brain.

Efflux of L-glutamic acid from synaptic plasma membrane vesicles requires external potassium. This requirement is saturated by concentrations of about 15 mequiv/L potassium. In the absence of potassium, L-glutamic acid can be released from the vesicles in the presence of external L-glutamic acid. This stimulation does not require external sodium but is dependent on the external concentration of L-glutamic acid. Half-maximal effects are obtained by concentrations of about 1 microM which are very similar to the apparent Km for L-glutamic acid influx. Efflux of labeled glutamate driven by external sodium plus glutamate requires internal sodium. These findings suggest that the transporter displays an asymmetric behavior toward sodium. This ion dissociates much more slowly than L-glutamic acid on the external surface of the membrane but not on the internal surface. Furthermore, it appears that the transporter translocates potassium in a step distinct from the L-glutamic acid translocation step. The simplest explanation is that upon translocation of sodium and L-glutamic acid and their release to the inside, potassium binds to the transporter, enabling it to return to the outside to allow initiation of a new transport cycle.

Animals↗

Absence of glutamic acid decarboxylase antibodies in childhood epilepsies.

Glutamic acid decarboxylase antibodies are present in some patients with therapy-resistant epilepsy. The authors measured glutamic acid decarboxylase antibodies in an unselected population of 114 children with different types of epilepsy. Three children with temporal lobe epilepsy and six children with various other types of epilepsy had intractable epilepsy. None of the children tested positive for glutamic acid decarboxylase antibodies. The study suggests that glutamic acid decarboxylase antibody testing cannot be recommended in unselected cases of childhood epilepsy.

Antibodies↗

The release of glutamic acid from isolated brain tissues.

The glutamic acid and other primary amines released spontaneously and by electrical pulses from rat brain caudate and cortex were measured by the fluorescamine method. Electrical pulses evoked a transient release of glutamic acid which was greater from caudate tissue. Both morphine and reserpine, in vivo, inhibited the spontaneous glutamic acid release but not the loss of glutamic acid due to pulses.

Animals↗

Localization of L-glutamic acid decarboxylase mRNA in monkey and human retina by in situ hybridization.

Immunocytochemical studies with gamma-aminobutyric acid (GABA) antibodies and glutamic acid decarboxylase antibodies have shown that the primate retina contains GABAergic amacrine, interplexiform, and displaced amacrine cells. In addition, subpopulations of photoreceptors and horizontal cells have also been suggested to be GABAergic in this retina. In the present study, we have used in situ hybridization to localize GABAergic neurons in human and monkey retinas. In situ hybridizations were carried out with 35S-labeled DNA and RNA probes derived from human and cat glutamic acid decarboxylase cDNA clones. In the monkey retina, labeled cells were present in the inner nuclear and ganglion cells layers. The outer nuclear layer or the inner segment layer had only background levels of labeling. In the inner nuclear layer, all labeled somata were located in the vitread-half bordering the inner nuclear layer/inner plexiform layer boundary. These cells constituted approximately 83% of all labeled cells. Labeled cells were also seen in the ganglion cell layer. In the human retina, labeled somata were observed only in the inner nuclear and the ganglion cell layers. In the inner nuclear layer, the majority of labeled cells were located close to the inner nuclear layer/inner plexiform layer boundary although a minor population of labeled somata (approximately 20%) were found deeper in the inner nuclear layer. The distribution of glutamic acid decarboxylase mRNA-containing cells we observed is in good agreement with the known location of GABAergic neurons. We, however, did not find glutamic acid decarboxylase mRNA in either horizontal cells or photoreceptors in monkey and human retina.

Animals↗

Cloning and primary structure of a human islet isoform of glutamic acid decarboxylase from chromosome 10.

Glutamic acid decarboxylase (GAD; glutamate decarboxylase, L-glutamate 1-carboxy-lyase, EC 4.1.1.15), which catalyzes formation of gamma-aminobutyric acid from L-glutamic acid, is detectable in different isoforms with distinct electrophoretic and kinetic characteristics. GAD has also been implicated as an autoantigen in the vastly differing autoimmune disease stiff-man syndrome and insulin-dependent diabetes mellitus. Despite the differing GAD isoforms, only one type of GAD cDNA (GAD-1), localized to a syntenic region of chromosome 2, has been isolated from rat, mouse, and cat. Using sequence information from GAD-1 to screen a human pancreatic islet cDNA library, we describe the isolation of an additional GAD cDNA (GAD-2), which was mapped to the short arm of human chromosome 10. Genomic Southern blotting with GAD-2 demonstrated a hybridization pattern different from that detected by GAD-1. GAD-2 recognizes a 5.6-kilobase transcript in both islets and brain, in contrast to GAD-1, which detects a 3.7-kilobase transcript in brain only. The deduced 585-amino acid sequence coded for by GAD-2 shows less than 65% identity to previously published, highly conserved GAD-1 brain sequences, which show greater than 96% deduced amino acid sequence homology among the three species. The function of this additional islet GAD isoform and its importance as an autoantigen in insulin-dependent diabetes remain to be determined.

Amino Acid Sequence↗

Effects of morphine-3-glucuronide and morphine on the K+-evoked release of [3H]-glutamic acid and [14C]-gamma-aminobutyric acid from rat brain synaptosomes.

The effects of morphine-3-glucuronide (M3G) and morphine on the K+-evoked release of [14C]-gamma-aminobutyric acid (GABA) and [3 H]-glutamic acid were investigated in rat brain synaptosomes using superfusion techniques. K+-evoked release of both [14C]-GABA and [3H]-glutamic acid from rat brain synaptosomes was eliminated in the absence of calcium, indicating that K+-evoked neurotransmitter release was from vesicular stores in a manner analagous to that which occurs in vivo following an action potential (1). Addition of M3G or morphine in a range of concentrations (0.1-10 microM) to the superfusion medium did not alter the K+-evoked release of [14C]-GABA or [3H]-glutamic acid from rat brain synaptosomes, suggesting that the CNS excitation observed following central administration of M3G (2-5) and supra-analgesic doses of morphine (2,3,6,7) does not occur by a generalized inhibition of GABA release or facilitation of glutamic acid release from pre-synaptic nerve terminals.

Action Potentials↗